aTyr Pharma, Inc.
ATYRNASDAQHealthcare● Active
$0.47
+$0.03(+7.22%)
Market Cap$46476269
P/E Ratio—
52W High$7.29
52W Low$0.395
aTyr Pharma, Inc. (ATYR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATYR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19M | $0.23M | $0.35M | $10.39M | $0.00M |
| Cost of Revenue | $1.55M | $0.00M | $0.00M | $1.70M | $1.30M |
| Gross Profit | ($1.36M) | $0.23M | $0.35M | $8.69M | ($1.30M) |
| Gross Margin %(computed) | -717.37% | 100.00% | 100.00% | 83.68% | — |
| Operating Expenses | |||||
| R&D Expenses | $60.22M | $54.37M | $42.29M | $42.81M | $23.26M |
| G&A Expenses | $17.60M | $13.78M | $12.98M | $13.98M | $10.75M |
| Total Operating Expenses | $76.26M | $68.15M | $55.27M | $55.09M | $32.71M |
| Operating Income | ($77.63M) | ($67.91M) | ($54.92M) | ($46.40M) | ($34.02M) |
| Operating Margin %(computed) | — | — | — | -446.79% | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($74.12M) | ($64.02M) | ($50.40M) | ($45.34M) | ($33.78M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($74.12M) | ($64.02M) | ($50.39M) | ($45.34M) | ($33.77M) |
| Net Margin %(computed) | — | — | — | -436.53% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Wtd Avg Shares | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M |
| EBITDA | ($76.07M) | ($66.37M) | ($52.18M) | ($44.71M) | ($32.47M) |
| EBITDA Margin %(computed) | — | — | — | -430.47% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more aTyr Pharma, Inc. data
About aTyr Pharma, Inc. (ATYR) Income Statement
aTyr Pharma, Inc. (ATYR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ATYR reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -717.37%), and net income of ($0.07B) — a net profit margin of -39009.47%.
Frequently asked questions
ATYR · 4 questionsaTyr Pharma, Inc. (ATYR) reported revenue of $0.00B for 2025, down 19.1% year-over-year.
ATYR revenueATYR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09